ReviewBioorganic & medicinal chemistry letters2013
HIV/AIDS eradication.
Review in Bioorganic & medicinal chemistry letters, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Initiation of Antiretroviral Therapy during Primary HIV Infection: Effects on the Latent HIV Reservoir, Including on Analytic Treatment Interruptions.AIDS reviews · 2020Pooled it
- Review
- Secreted factors induced by PKC modulators do not indirectly cause HIV latency reversal.Virology · 2023Article
- Prodrug Therapies for Infectious and Neurodegenerative Diseases.Pharmaceutics · 2022Review
- Contribution of Sex Differences to HIV Immunology, Pathogenesis, and Cure Approaches.Frontiers in immunology · 2022Review
- Tracking HIV Rebound following Latency Reversal Using Barcoded HIV.Cell reports. Medicine · 2020Article
- Prodrugs of PKC modulators show enhanced HIV latency reversal and an expanded therapeutic window.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidate.PloS one · 2019Article
- Triterpenoids from Ocimum labiatum Activates Latent HIV-1 Expression In Vitro: Potential for Use in Adjuvant Therapy.Molecules (Basel, Switzerland) · 2017Article
- Humanized Mouse Models for Human Immunodeficiency Virus Infection.Annual review of virology · 2017Review
- In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication.PLoS pathogens · 2017Article
- A clue to unprecedented strategy to HIV eradication: "Lock-in and apoptosis".Scientific reports · 2017Article
- Recent Insights into the HIV/AIDS Pandemic.Microbial cell (Graz, Austria) · 2016Review
- Comorbidities associated with HIV and antiretroviral therapy (clinical sciences): a workshop report.Oral diseases · 2016Article
- Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research.Journal of translational medicine · 2016Review
- Studies of retroviral infection in humanized mice.Virology · 2015Review
- Study of viral pathogenesis in humanized mice.Current opinion in virology · 2015Review
- Double trouble: HIV latency and CTL escape.Cell host & microbe · 2015Article
- Experimental Approaches for Eliminating Latent HIV.Forum on immunopathological diseases and therapeutics · 2015Article
- Elimination of HIV-1-Infected Primary T Cell Reservoirs in an In Vitro Model of Latency.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Antiretroviral therapy can inhibit HIV replication in patients and prevent progression to AIDS. However, it is not curative. Here we provide an overview of what antiretroviral drugs do and how the virus persists during therapy in rare reservoirs, such as latently infected CD4+ T cells. We also outline several innovative methods that are currently under development to eradicate HIV from infected individuals. These strategies include gene therapy approaches intended to create an HIV-resistant immune system, and activation/elimination approaches directed towards flushing out latent virus. This latter approach could involve the use of novel chemically synthesized analogs of natural activating agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.